Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABEO Abeona Therapeutics	$6.26 -0.2%	$6.21	$3.93 ▼ $7.32	$320.75M	1.55	636,456 shs	414,463 shs
ARCT Arcturus Therapeutics	$11.91 -0.6%	$13.15	$8.04 ▼ $25.88	$324.90M	2.26	359,176 shs	396,324 shs
AURA Aura Biosciences	$6.80 +3.8%	$6.55	$4.34 ▼ $12.38	$329.26M	0.46	166,105 shs	148,610 shs
AVTX Avalo Therapeutics	$8.93 +6.9%	$5.59	$3.39 ▼ $16.00	$90.41M	0.8	284,396 shs	392,428 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABEO Abeona Therapeutics	-0.16%	-3.54%	+7.38%	+18.79%	+41.63%
ARCT Arcturus Therapeutics	-0.58%	-3.17%	-19.47%	+8.47%	-36.41%
AURA Aura Biosciences	+3.82%	+0.89%	+3.19%	+30.02%	-16.97%
AVTX Avalo Therapeutics	+6.95%	+13.18%	+80.40%	+119.95%	-18.07%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABEO Abeona Therapeutics	3.8645 of 5 stars	3.5	1.0	4.5	2.9	2.5	0.0
ARCT Arcturus Therapeutics	2.7431 of 5 stars	3.6	2.0	0.0	2.6	2.5	0.6
AURA Aura Biosciences	1.9445 of 5 stars	3.6	0.0	0.0	2.1	3.3	0.0
AVTX Avalo Therapeutics	2.6724 of 5 stars	3.5	3.0	0.0	1.1	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABEO Abeona Therapeutics	3.00	Buy	$19.25	207.51% Upside
ARCT Arcturus Therapeutics	3.11	Buy	$54.00	353.40% Upside
AURA Aura Biosciences	3.25	Buy	$22.00	223.53% Upside
AVTX Avalo Therapeutics	3.00	Buy	$30.00	235.95% Upside

Current Analyst Ratings Breakdown

Latest AVTX, AURA, ARCT, and ABEO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/14/2025	ABEO Abeona Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
7/2/2025	ARCT Arcturus Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
7/2/2025	ARCT Arcturus Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Outperform ➝ Sector Outperform	$32.00 ➝ $35.00
6/2/2025	ABEO Abeona Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$19.00
6/2/2025	AVTX Avalo Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$15.00
5/28/2025	ARCT Arcturus Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$32.00
5/28/2025	AURA Aura Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$22.00
5/23/2025	AURA Aura Biosciences	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$19.00
5/16/2025	ABEO Abeona Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$21.00 ➝ $20.00
5/15/2025	ABEO Abeona Therapeutics	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/14/2025	ARCT Arcturus Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$50.00 ➝ $45.00

(Data available from 8/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABEO Abeona Therapeutics	$3.50M	91.50	N/A	N/A	$1.01 per share	6.20
ARCT Arcturus Therapeutics	$152.31M	2.12	N/A	N/A	$8.90 per share	1.34
AURA Aura Biosciences	N/A	N/A	N/A	N/A	$3.04 per share	N/A
AVTX Avalo Therapeutics	$440K	219.80	N/A	N/A	$12.80 per share	0.70

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABEO Abeona Therapeutics	-$63.73M	-$1.27	N/A	N/A	N/A	N/A	-118.82%	-52.48%	8/11/2025 (Estimated)
ARCT Arcturus Therapeutics	-$80.94M	-$2.53	N/A	N/A	N/A	-47.47%	-27.41%	-19.01%	8/11/2025 (Estimated)
AURA Aura Biosciences	-$86.92M	-$1.90	N/A	N/A	N/A	N/A	-58.63%	-49.74%	8/14/2025 (Estimated)
AVTX Avalo Therapeutics	-$35.13M	N/A	0.00	N/A	N/A	N/A	-50.10%	-35.76%	N/A

Latest AVTX, AURA, ARCT, and ABEO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	AURA Aura Biosciences	-$0.47	N/A	N/A	N/A	N/A	N/A
8/11/2025	Q2 2025	ABEO Abeona Therapeutics	-$0.39	N/A	N/A	N/A	$21.71 million	N/A
8/11/2025	Q2 2025	ARCT Arcturus Therapeutics	-$1.11	N/A	N/A	N/A	$17.64 million	N/A
8/7/2025	Q2 2025	AVTX Avalo Therapeutics	-$1.43	-$1.92	-$0.49	-$1.92	N/A	N/A
5/15/2025	Q1 2025	ABEO Abeona Therapeutics	-$0.35	-$0.24	+$0.11	-$0.24	N/A	N/A
5/15/2025	Q1 2025	AURA Aura Biosciences	-$0.47	-$0.55	-$0.08	-$0.55	N/A	N/A
5/12/2025	Q1 2025	ARCT Arcturus Therapeutics	-$1.58	-$0.52	+$1.06	-$0.52	$25.64 million	$29.38 million
5/12/2025	Q1 2025	AVTX Avalo Therapeutics	-$1.07	-$1.25	-$0.18	-$1.25	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABEO Abeona Therapeutics	N/A	N/A	N/A	N/A	N/A
ARCT Arcturus Therapeutics	N/A	N/A	N/A	N/A	N/A
AURA Aura Biosciences	N/A	N/A	N/A	N/A	N/A
AVTX Avalo Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABEO Abeona Therapeutics	0.27	4.90	4.90
ARCT Arcturus Therapeutics	0.06	5.64	5.64
AURA Aura Biosciences	N/A	11.06	11.06
AVTX Avalo Therapeutics	N/A	22.61	22.61

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABEO Abeona Therapeutics	80.56%
ARCT Arcturus Therapeutics	94.54%
AURA Aura Biosciences	96.75%
AVTX Avalo Therapeutics	87.06%

Insider Ownership

Company	Insider Ownership
ABEO Abeona Therapeutics	6.90%
ARCT Arcturus Therapeutics	16.60%
AURA Aura Biosciences	5.40%
AVTX Avalo Therapeutics	3.03%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABEO Abeona Therapeutics	90	51.16 million	47.63 million	Optionable
ARCT Arcturus Therapeutics	180	27.12 million	22.62 million	Optionable
AURA Aura Biosciences	50	50.27 million	47.55 million	Not Optionable
AVTX Avalo Therapeutics	40	10.83 million	10.50 million	Not Optionable

AVTX, AURA, ARCT, and ABEO Headlines

Recent News About These Companies

Avalo Therapeutics: Avalo Reports Second Quarter 2025 Financial Results and Recent Business Updates

August 8 at 7:46 PM | finanznachrichten.de

Avalo Reports Second Quarter 2025 Financial Results and Recent Business Updates

August 7 at 7:00 AM | globenewswire.com

Avalo Therapeutics (AVTX) Expected to Announce Quarterly Earnings on Monday

August 5, 2025 | marketbeat.com

Brokerages Set Avalo Therapeutics, Inc. (NASDAQ:AVTX) Target Price at $30.00

July 31, 2025 | americanbankingnews.com

Avalo Therapeutics, Inc. (NASDAQ:AVTX) Given Consensus Recommendation of "Buy" by Brokerages

July 28, 2025 | marketbeat.com

Avalo Therapeutics (NASDAQ:AVTX) Stock Price Down 0.6% - What's Next?

July 25, 2025 | marketbeat.com

NASDAQ:AVTX Financials | Avalo Therapeutics Inc - Investing.com

July 11, 2025 | investing.com

Avalo Adds Dr. Rita Jain to Board as LOTUS Trial Advances

July 3, 2025 | msn.com

Avalo Therapeutics to Participate in Upcoming Investor Conferences

June 23, 2025 | globenewswire.com

Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors

June 18, 2025 | globenewswire.com

H.C. Wainwright upgrades Avalo Therapeutics stock to buy

June 4, 2025 | uk.investing.com

Avalo Therapeutics Announces Leadership Change and Updates on AVTX-009 Phase 2 Trial for Hidradenitis Suppurativa

May 13, 2025 | nasdaq.com

AVALO THERAPEUTICS Earnings Results: $AVTX Reports Quarterly Earnings

May 13, 2025 | nasdaq.com

Tango dances away from preclinical work to extend cash runway, while Avalo lays out spending options

May 12, 2025 | fiercebiotech.comF

Avalo Therapeutics: Avalo Reports First Quarter 2025 Financial Results and Recent Business Updates

May 12, 2025 | finanznachrichten.de

Avalo Reports First Quarter 2025 Financial Results and Recent Business Updates

May 12, 2025 | globenewswire.com

Why Avalo Therapeutics, Inc.’s (AVTX) Stock Is Down 5.56%

May 5, 2025 | aaii.comA

Why Avalo Therapeutics, Inc.’s (AVTX) Stock Is Up 5.82%

May 2, 2025 | aaii.comA

Avalo Therapeutics to Participate in The Citizens Life Sciences Conference

April 30, 2025 | globenewswire.com

Seven new option listings and one option delisting on April 16th

April 17, 2025 | markets.businessinsider.com

Avalo Therapeutics Reports 2024 Financial Results

April 15, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Short Squeeze Candidates With Big Catalysts on the Horizon
By Dan Schmidt | July 25, 2025
View 3 Short Squeeze Candidates With Big Catalysts on the Horizon
Chipotle: Too Spicy for Smart Money to Resist After Stock Split
By Jeffrey Neal Johnson | July 11, 2025
View Chipotle: Too Spicy for Smart Money to Resist After Stock Split
Top 220 Most Beloved Local Businesses Across the U.S. [2025 Survey]
By MarketBeat Staff | July 29, 2025
View Top 220 Most Beloved Local Businesses Across the U.S. [2025 Survey]
3 Fast Food Stocks That Won’t Give You Indigestion Right Now
By Brian O'Connell | July 16, 2025
View 3 Fast Food Stocks That Won’t Give You Indigestion Right Now
How Texas Roadhouse Is Winning in a Changing Consumer Market
By Dan Schmidt | July 14, 2025
View How Texas Roadhouse Is Winning in a Changing Consumer Market

AVTX, AURA, ARCT, and ABEO Company Descriptions

Abeona Therapeutics NASDAQ:ABEO

$6.26 -0.01 (-0.16%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$6.35 +0.09 (+1.45%)

As of 08/8/2025 06:15 PM Eastern

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.

Arcturus Therapeutics NASDAQ:ARCT

$11.91 -0.07 (-0.58%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$11.95 +0.04 (+0.34%)

As of 08/8/2025 06:59 PM Eastern

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Aura Biosciences NASDAQ:AURA

$6.80 +0.25 (+3.82%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$6.81 +0.01 (+0.15%)

As of 08/8/2025 05:46 PM Eastern

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Avalo Therapeutics NASDAQ:AVTX

$8.93 +0.58 (+6.95%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$9.03 +0.10 (+1.13%)

As of 08/8/2025 07:34 PM Eastern

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time